HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $41 Price Target
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $41 Price Target
HC Wainwright & Co.重申買入Syndax Pharmicals，維持41美元的目標股價
HC Wainwright & Co. analyst Edward White reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $41 price target.
HC Wainwright & Co. 分析師愛德華·懷特重申Syndax Pharmicals（納斯達克股票代碼：SNDX）的買入並維持41美元的目標股價。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。